DVT Archives - Carey Danis & Lowe

Yaz Lawsuit Cites Bayer’s Lack of Blood Clot Risk Warning

By | Pharmaceutical litigation, Uncategorized, Yaz/Yasmin

yaz_lawsuit_yasmin_side_effects_lawsuits_dvt_blood_clot_settlementsIn early September, a woman who suffered from a deep vein thrombosis (DVT) in her right leg two years ago filed a Yaz lawsuit. According to a recent article in The Pennsylvania Record, the plaintiff, Dana Dougherty, filed her Yaz lawsuit alleging that the hormone present in Yaz, drospirenone, led to her health problems.

The lawsuit goes on to claim that the maker of Yaz, Bayer Pharmaceuticals, put the oral contraceptive on the market neglecting to include proper warnings about the risks of blood clots, DVT, and other serious side effects.

In a warning released by the U.S. Food and Drug Administration (FDA) in April 2012, they provided information about the association between oral contraceptives that contain the hormone drospirenone, such as Yaz and Yasmin, and the increased risk of developing a blood clot. The FDA pointed out that, according to currently available information, blood clot formation has a stronger link to drospirenone oral contraceptives than oral contraceptives that contain other types of hormones.

The British Medical Journal published an oft-cited study in August 2009 about the increased risk of blood clot development in patients using different types of oral contraceptives. When looking at patients using an oral contraceptive containing drospirenone, the researchers recorded a six-fold increase in the risk of blood clot formation when compared to individuals not using an oral contraceptive.

Researchers have also reported a considerably increased risk of blood clot formation and other venous complications during the first six months of using a drospirenone-containing oral contraceptive like Yaz, Yasmin, or Ocella.

As a national law firm that represents women who claim to have been injured by the use of Yaz, Yasmin, or Ocella, Carey Danis & Lowe has provided expert legal counsel in numerous cases that cite similar claims about insufficient warning about blood clot risks.

In addition to the risk of blood clot formation, plaintiffs who have filed Yaz and Yasmin lawsuits have also linked the oral contraceptives to heart attack, stroke, brain hemorrhage, and pulmonary embolism.

Carey Danis & Lowe Yaz and Yasmin lawyers are currently taking cases. For a free legal evaluation and to speak with one of our medical experts, contact Carey Danis & Lowe today to learn about your legal options.

Share your story with Carey Danis & Lowe by calling us at 800.721.2519, or by submitting a personal injury claim form.

Contraceptive Nuvaring Linked to Blood Clots and Stroke

By | NuvaRing, Pharmaceutical litigation, Uncategorized

Published November 12, 2012 by LawsuitInformation.org

Contraceptive Nuvaring Linked to Blood Clots and StrokeNuvaring is a contraceptive device manufactured by Organon. It was approved by the U.S. Food and Drug Administration (FDA) in 2001. Organon developed and manufactured Nuvaring on the premise of introducing a new form of birth control, one that would supposedly be easier for women to use.

However, it soon became apparent after the release of Nuvaring that there were serious issues with the contraceptive device. Questions began to arise as to the verity of Organon’s marketing campaign promoting Nuvaring, especially regarding third-generation hormones and Nuvaring’s unique hormonal release method.

As the Nuvaring is a contraceptive device used as a vaginal insert, the release of hormones into a woman’s body occurs differently than through oral contraceptives, such as birth control pills. Due to the placement of the Nuvaring inside of a woman’s body, the hormones are released directly into the bloodstream.

With oral contraceptives, hormonal release occurs primarily in the digestive tract. It is thought that the direct release of hormones into the bloodstream has been the cause of deadly blood clots in women who have used Nuvaring.

According to a CBS News report released in the fall of 2012, incidents of women suffering from Nuvaring-related blood clots, strokes, pulmonary embolisms, and deep vein thrombosis (DVT) have surpassed 1,000 cases reported to the FDA. The link between Nuvaring and blood clots leading to strokes or death are concurred through a study published by the British Medical Journal in May 2012, which demonstrated a correlation between the use of Nuvarings, and other vaginally inserted, ring-shaped contraceptives, and a 90% increased risk of blood clot development. In June 2012, the New England Journal of Medicine published a study with similar findings.

Trials for Nuvaring lawsuits are set to start on May 6, 2013, according to U.S. Federal District Judge Rodney W. Sippel. A federal Multi-District Litigation (MDL) court has been established in Missouri to hear the Nuvaring lawsuits.

If you have suffered from blood clots, stroke, pulmonary embolism, or DVT as a result of using a Nuvaring, you may be entitled to receive compensation for your undue suffering. Our attorneys at Carey Danis & Lowe are dedicated to assisting clients through providing them with expert legal advice regarding pharmaceutical product liability litigation.

To file a Nuvaring lawsuit, contact an experienced Nuvaring lawyer at Carey Danis & Lowe today.

Federal Trade Commission Concludes Investigation into Bayer Pharmaceuticals and Yasmin Patent Litigation

By | Pharmaceutical litigation, Uncategorized, Yaz/Yasmin

Published October 12, 2012 by LawsuitInformation.org

Federal Trade Commission Concludes Investigation into Bayer Pharmaceuticals and Yasmin Patent LitigationIn recent news regarding Bayer Pharmaceuticals, the German pharmaceutical giant responsible for the manufacture of Yaz and Yasmin, the Federal Trade Commission made the decision to terminate its investigation into a patent settlement between Bayer and Teva Pharmaceuticals.

In 2008, the two pharmaceutical companies reached an agreement in regards to Bayer’s claim that Barr Laboratories, which was ultimately purchased by Teva Pharmaceuticals, overstepped the boundaries of intellectual property protecting Bayer’s Yasmin patent. The 2008 settlement drew the attention of the FTC, and led to a four year investigation into the settlement agreement’s possible antitrust violations.

Though the investigation has ended, Bayer Pharmaceuticals is still tied up in a Multi-District Litigation in the Southern District of Illinois regarding a large number of Yaz and Yasmin lawsuits.

The U.S. Food and Drug Administration released data last October 2011 regarding a Yaz and Yasmin study they conducted in order to determine the drug’s link to the development of blood clots in women. The FDA’s research indicated that among the approximately 800,000 women, they recorded an increased risk of suffering from the development of a blood clot.

It is believed that the chemical drospirenone, which is present in both Yaz and Yasmin, causes health complications in women. The presence of drospirenone in the body elevates levels of potassium, and thus, puts women at a higher risk of developing a blood clot.

Yaz and Yasmin side effects include:

  • Blood clots
  • Stroke
  • Deep Vein Thrombosis (DVT)
  • Pulmonary Embolism

Deep Vein Thrombosis is a serious health condition in which a blood clot forms in a deep vein, most often in a vein in the leg. DVT has been known to cause extreme pain in the location of the blood clot. The danger of DVT is the blood clot migrating to the lungs or brain, causing a more serious and life-threatening condition.

Pulmonary Embolism occurs when a blood clot enters an artery in the lungs, thus obstructing the normal flow of blood to the lungs, and resulting in a lack of oxygen delivery throughout the entire body.

If you or a loved one has suffered from a blood clot caused by the use of either Yaz or Yasmin, you may be eligible to receive compensation for your suffering. To file a Yaz lawsuit or a Yasmin lawsuit, contact our experienced pharmaceutical litigation lawyers at Carey Danis & Lowe.

Yaz/Yasmin DVT & Pulmonary Embolism Settlements Progressing

By | Pharmaceutical litigation, Uncategorized, Yaz/Yasmin

Published July 10, 2012 by LawsuintInformation

Yaz Deep Vein Thrombosis & Pulmonary Embolism Settlements ProgressingAs a Yaz Pulmonary Embolism, Deep Vein Thrombosis Attorney I have written extensively about the risks inherent in birth control pills containing Drospirenone.

According to status report held on June 22, in the U.S. District Court for the Southern District of Illinois, Bayer has reached agreements with about 33 different law firms to resolve at least 1,444 Yaz Deep Vein Thrombosis, Stroke and Pulmonary Embolism claims.

According to Bloomberg News, as of late April, Bayer faced 11,900 lawsuits over Yaz and its sister drug Yasmin in the U.S. with about 14,000 plaintiffs. Experts predict that the company may have to pay up to $2.65 billion to settle all of the pending cases.

Bayer, the manufacturer of Yaz, Yasmin and Ocella, began settlement negotiations earlier in January, with women who claimed venous thromboembolism blood clot-related personal injuries allegedly caused by side effects of these oral contraceptive birth control pills.

Yaz Federal MDL

All federal cases have been centralized for pretrial proceedings in the U.S. District Court for the Southern District of Illinois. These lawsuits are consolidated as part of an MDL, or multidistrict litigation.

No Venous Thrombotic Bellwether Trials

According to the hearing conference minutes, the judge overseeing the MDL litigation, opined that there are not going to be any bellwether cases involving venous thrombotic injuries. The reason apparently was because the settlement process is continuing to work to resolve the remaining injury cases.

Bayer is only settling Yaz lawsuits involving a pulmonary embolism or deep vein thrombosis injury at this time. A deep vein thrombosis (DVT) is a blood clot that occurs in the deep veins of the legs or pelvis. A pulmonary embolism occurs when the leg blood clot breaks off, travels through the blood stream and becomes lodged in the lung.

34 Plaintiffs Fill New Yaz and Yasmin Lawsuit

By | Pharmaceutical litigation, Uncategorized, Yaz/Yasmin

Published May 19, 2012 on Seedol

In addition to the nearly 12,000 Yaz and Yasmin Lawsuits that have been filed a new Yaz Lawsuit and Yasmin Lawsuit was filed in the Superior Court of California, Los Angeles County in late April. This new Y Lawsuit names Bayer Healthcare LLC; Bayer Pharmaceuticals Corporation; Bayer Healthcare Pharmaceuticals Inc.; Berlex Laboratories, Inc.; Berlex, Inc.; Bayer Schering Pharma AG; Bayer AG; McKesson Corporation; Barr Laboratories, Inc; Barr Pharmaceuticals LLC; Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries Ltd as defendants. The Yaz Lawsuit wsa filed on behalf of approxitmately 34 Plaintiffs.

As with previous Yaz Lawsuits this suit alleges that the Defendants knew and were aware or should have been aware that the PRODUCTS had not been sufficiently tested, was defective in its design and testing, and lacked adequate and sufficient warnings.

The suit also alleges that the Defendants knew or should have known that the PRODUCTS had a potential to, could, and would cause severe and grievous injury and death to the users of said product, and that it was inherently dangerous in a manner that exceeded any purported, inaccurate and downplayed warnings.

The suit in question is bases on numerous allegations other than those listed above with the majority of the allegations in the complaint being centered around the defendants “Failure to Warn” the plaintiffs of the risks associated with the use of Yaz or Yazmin.

If you took Yaz or Yazmin and suffered a blood clot reltated injury such as a DVT, a pulmonary emoblishm, a stroke or other blood clot related injury it is not too late to file a Yaz Lawsuit or Yazmin Lawsuit to be compensated for your medical bills, pain and suffering and other loses. Visit Carey Danis & Lowe to file your claim.